Company Monitoring Page for Novartis

latest headlines for company on cafepharma

In Novartis' newest Cosentyx push, active, real-life patients take center stage
Fierce Pharma
Mon, 10/9/17 - 10:54 am
Tags:
Novartis, Cosentyx, drug ads, psoriatic arthritis
Lilly wards off another Alimta patent challenge, this time through IPR
Fierce Pharma
Fri, 10/6/17 - 11:42 am
Tags:
Eli Lilly, Alimta, patents, IPR, lung cancer, Neptune, generics, Novartis, Sandoz
As CAR-T launch ramps up in U.S., Novartis' Narasimhan looks to convince Japan on performance-based pricing
Fierce Pharma
Thu, 10/5/17 - 06:16 pm
Tags:
Novartis, CAR-T, Vas Narasimhan, Japan, drug pricing, performance-based pricing
Big Pharma Doesn't Want Health Outcomes To Sway Pricing -- At Least Not Yet
Forbes
Fri, 09/29/17 - 11:53 am
Tags:
Big Pharma, drug pricing, gene therapy, Novartis, Kymriah
Why would Novartis buy a $2.6B radiotherapy maker? Its neuroendocrine franchise, analyst says
Fierce Pharma
Thu, 09/28/17 - 06:28 pm
Tags:
Novartis, radiotherapy, M&A, Advanced Accelerator Application, neuroendocrine
Lilly steps up to rival Pfizer, Novartis with Verzenio breast cancer approval
Fierce Pharma
Thu, 09/28/17 - 06:24 pm
Tags:
Eli Lilly, Pfizer, Novartis, Verzenio, breast cancer, Ibrance, Kisqali
Buyout buzz: Novartis has been kicking the tires at AAA as FDA reviews Lutathera — report
Endpoints
Thu, 09/28/17 - 11:08 am
Tags:
Novartis, FDA, Lutathera, M&A, Advanced Accelerator Application
Premium price for Novartis' CAR-T sparks pushback from top PBM
BioPharma Dive
Mon, 09/25/17 - 07:23 pm
Tags:
Novartis, Kymriah, CAR-T, drug pricing, Express Scripts, PBMs
Two years on, Allergan’s $1.7B NASH drug still looks weak — at best
Endpoints
Fri, 09/22/17 - 11:16 am
Tags:
Allergan, NASH, Novartis, Cenicriviroc
Pharma executives wary of value-based deals, but see the potential benefits: PwC
Fierce Pharma
Fri, 09/22/17 - 11:13 am
Tags:
value-based contracts, Amgen, Novartis, Sanofi, Merck
New pharma CEOs to face payer, pricing challenges
Medical Marketing and Media
Thu, 09/21/17 - 10:15 pm
Tags:
Pharma CEOs, Novartis, Teva Pharmaceutical, Kåre Schultz, Vasant Narasimham, payers, drug pricing
On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy
Xconomy
Tue, 09/19/17 - 08:43 am
Tags:
CAR-T, Novartis, Seattle Children's, pediatric cancer, ALL, gene therapy
Novartis touts 5-year Cosentyx data as it works to hold top spot in psoriasis
Fierce Pharma
Wed, 09/13/17 - 09:43 pm
Tags:
Novartis, Cosentyx, psoriasis
#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage
Endpoints
Mon, 09/11/17 - 09:17 am
Tags:
ESMO, Eli Lilly, Pfizer, Novartis, abemaciclib, breast cancer
An accurate analysis of the differences between Swiss companies Roche and Novartis
GoInPharma
Sat, 09/9/17 - 01:22 pm
Tags:
Novartis, Roche, Switzerland
Departing Novartis CEO Sets His Eyes On Silicon Valley
Forbes
Thu, 09/7/17 - 09:51 am
Tags:
Pharma CEOs, Novartis, Joe Jimenez, Silicon Valley
Novartis charged much more in the U.S. for some drugs than in other countries
Stat
Tue, 09/5/17 - 10:05 pm
Tags:
Novartis, drug pricing
New Novartis CEO Narasimhan will face plenty of obstacles despite CAR-T triumph
Fierce Biotech
Tue, 09/5/17 - 11:10 am
Tags:
Novartis, Pharma CEOs, Vas Narasimhan, CAR-T
Novartis follows up on big CAR-T win by naming Vas Narasimhan as its new CEO
Endpoints
Mon, 09/4/17 - 10:13 am
Tags:
Novartis, Pharma CEOs, CAR-T, Vas Narasimhan, Joe Jimenez
At $475,000, new cancer drug raises thorny questions about drug pricing — and value
Stat
Mon, 09/4/17 - 10:11 am
Tags:
drug pricing, CAR-T, Novartis, Kymriah

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.